Last reviewed · How we verify
Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine treatment landscape brief
- Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine treatment updates RSS
Frequently asked questions about Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine
What drugs treat Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine?
Tracked treatments include Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose.
What is the treatment for Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine?
Standard treatment for Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine includes Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine patent cliff · Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine CI report
- Treatment: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing